<DOC>
	<DOCNO>NCT02305030</DOCNO>
	<brief_summary>Single-centre , open-label , fixed-sequence design consist 2 period separate washout period least 14 day .</brief_summary>
	<brief_title>Effect Opicapone Steady State Warfarin Pharmacokinetics</brief_title>
	<detailed_description>Single-centre , open-label , fixed-sequence design consist 2 period separate washout period least 14 day . In Period 1 , single dose 25 mg warfarin administer alone . In Period 2 , subject receive 475 mg OPC , Day 1 D2 follow 50 mg OPC daily 5 day ( D3 D7 ) . On D8 , 50 mg OPC administer single dose 25 mg warfarin .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Opicapone</mesh_term>
	<mesh_term>Warfarin</mesh_term>
	<criteria>A sign date informed consent form studyspecific screen procedure perform , Male female subject age 18 45 year , inclusive , Body mass index ( BMI ) 18 30 kg/m2 , Healthy determine prestudy medical history , physical examination , vital sign , complete neurological examination 12lead electrocardiogram ( ECG ) , Negative test hepatitis B surface antigen ( HBsAg ) , antihepatitis C virus ( HCV ) antibodies antihuman immunodeficiency virus ( HIV ) antibodies screen , Clinical laboratory test result clinically acceptable screen admission inpatient period , Negative screen alcohol drug abuse screen admission inpatient period , Nonsmokers exsmokers least 3 month , Able participate , willing give write informed consent comply study restriction , Able swallow high number capsule within short time frame , If female : Was childbearing potential reason surgery , childbearing potential , used effective nonhormonal method contraception ( intrauterine device intrauterine system ; condom occlusive cap [ diaphragm cervical vault cap ] spermicidal foam gel film cream suppository ; true abstinence ; vasectomize male partner , provide sole partner subject ) entire duration study , Negative serum pregnancy test screen negative urine pregnancy test admission inpatient period . Any clinically relevant history presence respiratory , gastrointestinal , renal , hepatic , haematological , lymphatic , neurological , cardiovascular , psychiatric , musculoskeletal , genitourinary , immunological , dermatological , endocrine , connective tissue diseases disorder , clinically relevant surgical history , Any personal family history haemostatic disorder , Any personal family history bleed complication surgery tooth extraction , nose gingival bleeding , haemorrhagic diathesis , Any clinically relevant finding laboratory test , particularly abnormality coagulation test liver function test , History relevant atopy drug hypersensitivity , History alcoholism and/or drug abuse , Current consumption 14 unit alcohol per week [ 1 unit alcohol = 280 mL beer ( 34° ) = 100 mL wine ( 1012° ) = 30 mL spirit ( 40° ) ] , Any significant infection know inflammatory process screen admission treatment period ; acute gastrointestinal symptom ( e.g. , nausea , vomit , diarrhoea , heartburn ) time screen admission treatment period , Use medicine within 2 week admission first period could affect subject 's safety study assessment , investigator 's opinion , intake prohibit medication ( i.e. , CYP2C9 inhibitor take within 1 week prior start administration study drug , CYP2C9 inducer take within 4 week prior dose ) , Previous use opicapone , Use investigational drug participation clinical trial within 3 month prior screen ; participation 2 clinical trial within 12 month prior screen , Blood donation receipt blood transfusion blood product within 3 month prior screen , Vegetarian , vegan medical dietary restriction , Not able communicate reliably investigator , Unlikely cooperate requirement study , Unwilling unable give write informed consent , CYP2C9 poor metaboliser , assess genotyping , If female : Pregnant breastfeeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>November 2014</verification_date>
</DOC>